company background image
4726 logo

Mycenax Biotech TPEX:4726 Stock Report

Last Price

NT$45.30

Market Cap

NT$9.3b

7D

-3.8%

1Y

28.1%

Updated

21 Nov, 2024

Data

Company Financials

4726 Stock Overview

Develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States. More details

4726 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Mycenax Biotech Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mycenax Biotech
Historical stock prices
Current Share PriceNT$45.30
52 Week HighNT$65.20
52 Week LowNT$34.90
Beta1.06
11 Month Change-10.12%
3 Month Change-15.33%
1 Year Change28.15%
33 Year Change14.54%
5 Year Change100.44%
Change since IPO155.93%

Recent News & Updates

Recent updates

Mycenax Biotech's (GTSM:4726) Earnings Are Of Questionable Quality

Apr 05
Mycenax Biotech's (GTSM:4726) Earnings Are Of Questionable Quality

Update: Mycenax Biotech (GTSM:4726) Stock Gained 38% In The Last Year

Jan 07
Update: Mycenax Biotech (GTSM:4726) Stock Gained 38% In The Last Year

Shareholder Returns

4726TW BiotechsTW Market
7D-3.8%-3.1%-0.8%
1Y28.1%2.0%29.0%

Return vs Industry: 4726 exceeded the TW Biotechs industry which returned 2% over the past year.

Return vs Market: 4726 matched the TW Market which returned 29% over the past year.

Price Volatility

Is 4726's price volatile compared to industry and market?
4726 volatility
4726 Average Weekly Movement3.9%
Biotechs Industry Average Movement4.5%
Market Average Movement4.5%
10% most volatile stocks in TW Market8.0%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 4726 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 4726's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001387Pei-Jiun Chenwww.mycenax.com.tw

Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States. The company develops monoclonal antibodies, bi-specific antibodies, fc-fusion proteins, recombinant proteins, peptides, protein conjugates (non-toxin), antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), as well as plasmids and DNA vaccines. It also provides process development solutions, including development of production cell lines, upstream and downstream process development, process scale-up, formulation development, and analytical methods; in-house analytical services; GMP manufacturing services, such as drug substance and products manufacturing, and cell banking; and manufacturing technologies.

Mycenax Biotech Inc. Fundamentals Summary

How do Mycenax Biotech's earnings and revenue compare to its market cap?
4726 fundamental statistics
Market capNT$9.34b
Earnings (TTM)-NT$536.33m
Revenue (TTM)NT$672.85m

13.9x

P/S Ratio

-17.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4726 income statement (TTM)
RevenueNT$672.85m
Cost of RevenueNT$956.07m
Gross Profit-NT$283.22m
Other ExpensesNT$253.11m
Earnings-NT$536.33m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.60
Gross Margin-42.09%
Net Profit Margin-79.71%
Debt/Equity Ratio38.4%

How did 4726 perform over the long term?

See historical performance and comparison